Detection of p53 point mutations by double-gradient, denaturing gradient gel electrophoresis

被引:24
作者
Gelfi, C
Righetti, SC
Zunino, F
Della Torre, G
Pierotti, MA
Righetti, PG
机构
[1] CNR, Ist Tecnol Biomed Avanzate, I-20131 Milan, Italy
[2] Ist Nazl Tumori, Div Expt Oncol B, I-20133 Milan, Italy
[3] Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy
[4] Univ Verona, Dept Agr & Ind Biotechnol, I-37100 Verona, Italy
关键词
p53; point mutations; DNA;
D O I
10.1002/elps.1150181533
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Genetic instability is a typical feature of tumor cells. This evidence has stimulated the development of rapid methods for detection of gene mutations. A new, improved protocol for denaturing gradient gel electrophoresis (DGGE), to screen for point mutations in genomic DNA, is reported: double gradient (DG) DGGE. In this technique, to the primary, denaturing gradient (typically 30-80% or 40-80% urea/formamide) a secondary gradient, colinear with the first, is superimposed: a porosity gradient (typically 6.5-12% polyacrylamide). The secondary gradient acts by recompacting smeared and diffuse bands of heteroduplexes, which are often indistinguishable from background fluorescence, and by augmenting the resolution between closely spaced homoduplex zones. This allows proper densitometric quantitation of the ratio of the two homoduplex bands. The reliability of this technique has been documented by detection of a number of mutations in exons 6 and 8 of the p53 gene which had escaped revelation by single-strand conformational polymorphism (SSCP) analysis. Additionally, the precise assessment of ratio of the doublet of homoduplex bands has allowed quantitation of the extent of p53 mutation in a mixed cell population extracted from a tumor specimen.
引用
收藏
页码:2921 / 2927
页数:7
相关论文
共 30 条
[1]  
BARTEK J, 1990, ONCOGENE, V5, P893
[2]  
Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020
[3]  
CARBONE D, 1991, ONCOGENE, V6, P1691
[4]   Double-gradient DGGE for optimized detection of DNA point mutations [J].
Cremonesi, L ;
Firpo, S ;
Ferrari, M ;
Righetti, PG ;
Gelfi, C .
BIOTECHNIQUES, 1997, 22 (02) :326-330
[5]  
DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1
[6]   GENE P53 MUTATIONS ARE RESTRICTED TO POORLY DIFFERENTIATED AND UNDIFFERENTIATED CARCINOMAS OF THE THYROID-GLAND [J].
DONGHI, R ;
LONGONI, A ;
PILOTTI, S ;
MICHIELI, P ;
DELLAPORTA, G ;
PIEROTTI, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1753-1760
[7]  
Fisher S.G., 1983, P NATL ACAD SCI USA, V80, P1579
[8]   Abnormal centrosome amplification in the absence of p53 [J].
Fukasawa, K ;
Choi, T ;
Kuriyama, R ;
Rulong, S ;
VandeVoude, GF .
SCIENCE, 1996, 271 (5256) :1744-1747
[9]   P53 MUTATIONS IN HUMAN LYMPHOID MALIGNANCIES - ASSOCIATION WITH BURKITT-LYMPHOMA AND CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
GAIDANO, G ;
BALLERINI, P ;
GONG, JZ ;
INGHIRAMI, G ;
NERI, A ;
NEWCOMB, EW ;
MAGRATH, IT ;
KNOWLES, DM ;
DALLAFAVERA, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) :5413-5417
[10]  
Gianazza E., 1979, ELECTROKINETIC SEPAR, P293